Selvaskandan2019_Article_NewStrategiesAndPerspectivesOn.pdf (925.52 kB)
Download file

New strategies and perspectives on managing IgA nephropathy.

Download (925.52 kB)
journal contribution
posted on 17.05.2019, 08:59 by Haresh Selvaskandan, Chee Kay Cheung, Masahiro Muto, Jonathan Barratt
IgA nephropathy is an inflammatory renal disease characterised by the deposition of IgA in the glomerular mesangium and is the most commonly reported primary glomerulonephritis worldwide. Thirty to forty percent of patients with the disease develop progressive renal function decline, requiring renal replacement therapy within two decades of diagnosis. Despite this, accurate individual risk stratification at diagnosis and predicting treatment response remains a challenge. Furthermore, there are currently no disease specific treatments currently licensed to treat the condition due to long standing challenges in the nature and prevalence of the disease. Despite this, there have been exciting recent advances in the field that may represent paradigm shifts in the way IgA nephropathy is managed in the near future. In this review, we explore the evidence base informing current approaches to management and explore new strategies and future directions in the diagnosis and management of IgA nephropathy.

History

Citation

Clinical and Experimental Nephrology, 2019, 23(5), pp 577–588

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

VoR (Version of Record)

Published in

Clinical and Experimental Nephrology

Publisher

Springer (part of Springer Nature) for Japanese Society of Nephrology (JSN)

eissn

1437-7799

Acceptance date

17/01/2019

Copyright date

2019

Available date

17/05/2019

Publisher version

https://link.springer.com/article/10.1007/s10157-019-01700-1

Language

en

Usage metrics

Categories

Licence

Exports